- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Dr. Michael Bonham Joins BioAI's Executive Team
Dr. Bonham joins as chief pathologist and executive medical director.
BioAI Health, a biotech company focused on the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, announced the addition of Michael Bonham MD, PhD to the growing BioAI executive team, where he will be joining as chief pathologist and executive medical director. Dr. Bonham will oversee all of BioAI's pharma-sponsored digital biomarker programs and help expand the company's growing pathology network.
"We're thrilled to have Dr. Bonham join our team to support our expanding digital biomarkers business," said Thomas Colarusso, CEO and Cofounder at BioAI. "He brings a wealth of knowledge and expertise in developing novel molecular diagnostic tests and digital pathology applications in Oncology."
